The present disclosure relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The disclosure also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The disclosure also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The disclosure also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present disclosure also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The disclosure also relates to transgenic animals or plants comprising nuclpeic acid molecules of the disclosure.本揭露係關於包括特異性結合MAdCAM較佳人類MAdCAM且起抑制MAdCAM作用之人類抗體及其抗原結合部分之抗體。本揭露亦關於人類抗MAdCAM抗體及其抗原結合部分。本揭露亦關於係嵌合抗體、雙特異性抗體、衍生抗體、單鏈抗體、或融合蛋白之部分的抗體。本揭露亦關於衍生自人類抗MAdCAM抗體之單離重鏈及輕鏈免疫球蛋白及編碼此類免疫球蛋白之核酸分子。本揭露亦關於製備人類抗MAdCAM抗體之方法、包含此等抗體之組成物、及使用該等抗體及組成物以供診斷及治療之方法。本揭露亦提供使用編碼構成該等人類抗MAdCAM抗體之該等重鏈及/或輕鏈免疫球蛋白分子之核酸分子之基因療法方法。本揭露亦關於包含本揭露之核酸分子之基因轉殖動物或植物。
